PUBLICATION
Evaluation of synergistic effect of Zerumbone with Cisplatin on anti-angiogenic potential in zebrafish model
- Authors
- Haripriya, D., Devi, J.S., Santhosh, A., Bupesh, G., Phukan, M.M., Panigrahi, J., Deb, C.R., Mathyazhagan, M., Kirubakaran, D., Saravanan, K.M., Padmanabhan, P., Mathe, D., Archunan, G.
- ID
- ZDB-PUB-250612-14
- Date
- 2025
- Source
- Medical oncology (Northwood, London, England) 42: 252252 (Journal)
- Registered Authors
- Keywords
- Anti-angiogenesis, Cisplatin, Combination therapy, Natural products, Zerumbone
- MeSH Terms
-
- Vascular Endothelial Growth Factor Receptor-2
- Angiogenesis Inhibitors*/administration & dosage
- Angiogenesis Inhibitors*/pharmacology
- Vascular Endothelial Growth Factor A/metabolism
- Cisplatin*/administration & dosage
- Cisplatin*/pharmacology
- Sesquiterpenes*/administration & dosage
- Sesquiterpenes*/pharmacology
- Antineoplastic Agents/pharmacology
- Drug Synergism
- Zebrafish
- Animals
- Disease Models, Animal
- Neovascularization, Pathologic*/drug therapy
- PubMed
- 40500427 Full text @ Med Oncol
Citation
Haripriya, D., Devi, J.S., Santhosh, A., Bupesh, G., Phukan, M.M., Panigrahi, J., Deb, C.R., Mathyazhagan, M., Kirubakaran, D., Saravanan, K.M., Padmanabhan, P., Mathe, D., Archunan, G. (2025) Evaluation of synergistic effect of Zerumbone with Cisplatin on anti-angiogenic potential in zebrafish model. Medical oncology (Northwood, London, England). 42:252252.
Abstract
Angiogenesis plays a critical role in cancer progression, highlighting the need for effective anti-angiogenic therapies. Zerumbone (ZER), a phytochemical compound, is known for its anti-angiogenic and anti-carcinogenic effects in various cancer cell lines. Cisplatin (CIS) is a widely used chemotherapeutic agent that effectively inhibits tumor growth. Combining CIS with anti-angiogenic agents like ZER may enhance the anticancer efficacy of CIS and improve treatment outcomes. This study aimed to evaluate the acute toxicity and anti-angiogenic effects of ZER, CIS, and the ZER + CIS combination in a zebrafish larval model. At higher concentrations, the ZER + CIS combination demonstrated only minimal toxicity. Both CIS and ZER exhibited significant anti-angiogenic activity, as indicated by the depletion of o-dianisidine-positive red blood cells in circulation compared to the control. The combination of ZER and CIS synergistically enhanced the down-regulation of VEGF-A (p < 0.001), VEGFR-2, NRP-1A, and NRP-2B, confirming the synergistic action of the two compounds. In conclusion, the combination of ZER and CIS exhibited superior anti-angiogenic effects compared to either treatment alone, suggesting a promising therapeutic strategy for cancer treatment.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping